Portal de Periódicos da CAPES

Comparison of Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting Tuberculosis Disease

2024; American Medical Association; Volume: 7; Issue: 4 Linguagem: Inglês

10.1001/jamanetworkopen.2024.4769

2574-3805

Tracy Ayers, Andrew Hill, Julia Raykin, Sarita A. Mohanty, Robert Belknap, Richard Brostrom, Renuka Khurana, Michael Lauzardo, Thaddeus L. Miller, Masahiro Narita, April C. Pettit, Alexandra Pyan, Katya Salcedo, Araxi Polony, Jennifer Flood, Lisa Pascopella, Amina Ahmed, Kaylynn Aiona, Juanita Lovato, Randall Reves, L Rivera Trujillo, Richard S. Garfein, Laura Farrow, Jason E. Stout, Sofia Zavala, Henry M. Blumberg, J Tapia, Alawode Oladele, Angela Largen, Susan E. Dorman, Gina Maltas, Elizabeth Munk, Maunank Shah, Aurimar Ayala, Wendy Cronin, Paul Saleeb, Michelle Haas, Yoseph Sorri, Christine Kozik, Marisa Moore, Chris Keh, Laura F. Romo, Joanne C Li, Stephanie Reynolds-Bigby, Marie Nancy Séraphin, Amy Board, Jeremy S. Gallups, Erica L. Stockbridge, David Horné, Kristen Atchley, Fernanda Maruri, Timothy R. Sterling, Amy Kerrigan, Alicia Wright, Kursten Lyon, Debra Turner,

Diagnosis and treatment of tuberculosis

Elimination of tuberculosis (TB) disease in the US hinges on the ability of tests to detect individual risk of developing disease to inform prevention. The relative performance of 3 available TB tests-the tuberculin skin test (TST) and 2 interferon-γ release assays (IGRAs; QuantiFERON-TB Gold In-Tube [QFT-GIT] and SPOT.TB [TSPOT])-in predicting TB disease development in the US remains unknown.